You have no items in your shopping cart.
Cart summary
Item 1 of 1
Trastuzumab - Research Grade Biosimilar
Catalog Number: orb1238040
| Catalog Number | orb1238040 |
|---|---|
| Category | Antibodies |
| Description | Trastuzumab - Research Grade Biosimilar |
| Target | ERBB2 |
| Clonality | Recombinant |
| Isotype | Human IgG1 |
| Conjugation | Unconjugated |
| Concentration | batch dependent |
| Buffer/Preservatives | PBS buffer pH 7.5 |
| Purity | > 95% |
| Immunogen | Humanized / ERBB2 (HER2, Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD_antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, NGL) [Homo sapiens] |
| UniProt ID | P04626 |
| Application notes | Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3]. |
| Antibody Type | Primary Antibody |
| Source | CHO cells |
| CAS Number | 180288-69-1 |
| Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks). Store at -20 °C 12 months. Store at -80°C long term. |
| Alternative names | NEU; NGL; HER2; TKR1; CD340; HER-2; VSCN2; MLN 19; Read more... |
| Note | For research use only |
| NCBI | P04626 |
SDS-PAGE Image
